Uncategorized

Uncategorized

New Releases from NCBI BookshelfThe acceptability of blood spot screening and genome sequencing in newborn screening: a systematic review examining evidence and frameworks [Internet].​The acceptability of blood spot screening and genome sequencing in newborn screening: a systematic review examining evidence and frameworks [Internet].

Population-wide newborn blood spot screening programmes are a successful public health intervention used to detect whether the baby is at

Uncategorized

New Releases from NCBI BookshelfClascoterone (Winlevi): Indication: For the topical treatment of acne vulgaris in patients 12 years of age and older: Reimbursement Recommendation [Internet].​Clascoterone (Winlevi): Indication: For the topical treatment of acne vulgaris in patients 12 years of age and older: Reimbursement Recommendation [Internet].

Canada’s Drug Agency (CDA-AMC) recommends that Winlevi not be reimbursed by public drug plans for the topical treatment of acne

Uncategorized

New Releases from NCBI BookshelfMomelotinib (Ojjaara): Indication: For the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk primary myelofibrosis (MF), post polycythemia vera myelofibrosis or post essential thrombocythemia MF who have moderate to severe anemia: Reimbursement Recommendation [Internet].​Momelotinib (Ojjaara): Indication: For the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk primary myelofibrosis (MF), post polycythemia vera myelofibrosis or post essential thrombocythemia MF who have moderate to severe anemia: Reimbursement Recommendation [Internet].

Canada’s Drug Agency (CDA-AMC) recommends that Ojjaara be reimbursed by public drug plans for the treatment of adult patients with

Uncategorized

New Releases from NCBI BookshelfZolbetuximab for Injection (Vyloy): Indication: In combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2-negative gastric or gastroesophageal junction adenocarcinoma whose tumours are Claudin 18.2 positive: Reimbursement Recommendation [Internet].​Zolbetuximab for Injection (Vyloy): Indication: In combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2-negative gastric or gastroesophageal junction adenocarcinoma whose tumours are Claudin 18.2 positive: Reimbursement Recommendation [Internet].

Canada’s Drug Agency (CDA-AMC) recommends that Vyloy should be reimbursed by public drug plans for the first-line treatment of adults

Scroll to Top